These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 29653222)

  • 21. Gemcitabine-loaded microbubble system for ultrasound imaging and therapy.
    Delaney LJ; Eisenbrey JR; Brown D; Brody JR; Jimbo M; Oeffinger BE; Stanczak M; Forsberg F; Liu JB; Wheatley MA
    Acta Biomater; 2021 Aug; 130():385-394. PubMed ID: 34082100
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A human clinical trial using ultrasound and microbubbles to enhance gemcitabine treatment of inoperable pancreatic cancer.
    Dimcevski G; Kotopoulis S; Bjånes T; Hoem D; Schjøtt J; Gjertsen BT; Biermann M; Molven A; Sorbye H; McCormack E; Postema M; Gilja OH
    J Control Release; 2016 Dec; 243():172-181. PubMed ID: 27744037
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of Loading Strategies to Improve Tumor Uptake of Gemcitabine in a Murine Orthotopic Bladder Cancer Model Using Ultrasound and Microbubbles.
    Ruan JL; Browning RJ; Yildiz YO; Bau L; Kamila S; Gray MD; Folkes L; Hampson A; McHale AP; Callan JF; Vojnovic B; Kiltie AE; Stride E
    Ultrasound Med Biol; 2021 Jun; 47(6):1596-1615. PubMed ID: 33707089
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Can intracellular drug delivery using hyaluronic acid functionalised pH-sensitive liposomes overcome gemcitabine resistance in pancreatic cancer?
    Tang M; Svirskis D; Leung E; Kanamala M; Wang H; Wu Z
    J Control Release; 2019 Jul; 305():89-100. PubMed ID: 31096017
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oxygen carrying microbubbles for enhanced sonodynamic therapy of hypoxic tumours.
    McEwan C; Owen J; Stride E; Fowley C; Nesbitt H; Cochrane D; Coussios CC; Borden M; Nomikou N; McHale AP; Callan JF
    J Control Release; 2015 Apr; 203():51-6. PubMed ID: 25660073
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MGMT expression affects the gemcitabine resistance of pancreatic cancer cells.
    Shi Y; Wang Y; Qian J; Yan X; Han Y; Yao N; Ma J
    Life Sci; 2020 Oct; 259():118148. PubMed ID: 32721465
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An ultrasound responsive microbubble-liposome conjugate for targeted irinotecan-oxaliplatin treatment of pancreatic cancer.
    Gao J; Nesbitt H; Logan K; Burnett K; White B; Jack IG; Taylor MA; Love M; Callan B; McHale AP; Callan JF
    Eur J Pharm Biopharm; 2020 Dec; 157():233-240. PubMed ID: 33222772
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Liposomal Gemcitabine, FF-10832, Improves Plasma Stability, Tumor Targeting, and Antitumor Efficacy of Gemcitabine in Pancreatic Cancer Xenograft Models.
    Matsumoto T; Komori T; Yoshino Y; Ioroi T; Kitahashi T; Kitahara H; Ono K; Higuchi T; Sakabe M; Kori H; Kano M; Hori R; Kato Y; Hagiwara S
    Pharm Res; 2021 Jun; 38(6):1093-1106. PubMed ID: 33961188
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Temperature-sensitive magnetic drug carriers for concurrent gemcitabine chemohyperthermia.
    Kim DH; Guo Y; Zhang Z; Procissi D; Nicolai J; Omary RA; Larson AC
    Adv Healthc Mater; 2014 May; 3(5):714-24. PubMed ID: 24574255
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Radioimmunotherapy of human pancreatic cancer xenografts in NOD-scid mice with [
    Boyle AJ; Cao PJ; Cai Z; Chan C; Hedley DW; Reilly RM
    Nucl Med Biol; 2020; 84-85():46-54. PubMed ID: 32062317
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antitumour activity of sunitinib in combination with gemcitabine in experimental pancreatic cancer.
    Awasthi N; Schwarz MA; Schwarz RE
    HPB (Oxford); 2011 Sep; 13(9):597-604. PubMed ID: 21843259
    [TBL] [Abstract][Full Text] [Related]  

  • 32. S-Adenosylmethionine synergistically enhances the antitumor effect of gemcitabine against pancreatic cancer through JAK2/STAT3 pathway.
    Liu Y; Bi T; Liu L; Gao Q; Shen G; Qin L
    Naunyn Schmiedebergs Arch Pharmacol; 2019 May; 392(5):615-622. PubMed ID: 30683944
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeted nuclear factor-kappaB suppression enhances gemcitabine response in human pancreatic tumor cell line murine xenografts.
    Waters JA; Matos J; Yip-Schneider M; Aguilar-Saavedra JR; Crean CD; Beane JD; Dumas RP; Suvannasankha A; Schmidt CM
    Surgery; 2015 Oct; 158(4):881-8; discussion 888-9. PubMed ID: 26209568
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gemcitabine loaded autologous exosomes for effective and safe chemotherapy of pancreatic cancer.
    Li YJ; Wu JY; Wang JM; Hu XB; Cai JX; Xiang DX
    Acta Biomater; 2020 Jan; 101():519-530. PubMed ID: 31629893
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeted delivery of a peripheral benzodiazepine receptor ligand-gemcitabine conjugate to brain tumors in a xenograft model.
    Guo P; Ma J; Li S; Guo Z; Adams AL; Gallo JM
    Cancer Chemother Pharmacol; 2001 Aug; 48(2):169-76. PubMed ID: 11561783
    [TBL] [Abstract][Full Text] [Related]  

  • 36. TIMP1 down-regulation enhances gemcitabine sensitivity and reverses chemoresistance in pancreatic cancer.
    Tan Y; Li X; Tian Z; Chen S; Zou J; Lian G; Chen S; Huang K; Chen Y
    Biochem Pharmacol; 2021 Jul; 189():114085. PubMed ID: 32522594
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment with gemcitabine and TRA-8 anti-death receptor-5 mAb reduces pancreatic adenocarcinoma cell viability in vitro and growth in vivo.
    DeRosier LC; Huang ZQ; Sellers JC; Buchsbaum DJ; Vickers SM
    J Gastrointest Surg; 2006 Nov; 10(9):1291-300; discussion 1300. PubMed ID: 17114015
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Aldehyde dehydrogenase 1A1 confers intrinsic and acquired resistance to gemcitabine in human pancreatic adenocarcinoma MIA PaCa-2 cells.
    Duong HQ; Hwang JS; Kim HJ; Kang HJ; Seong YS; Bae I
    Int J Oncol; 2012 Sep; 41(3):855-61. PubMed ID: 22710732
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dual delivery nanoscale device for miR-345 and gemcitabine co-delivery to treat pancreatic cancer.
    Uz M; Kalaga M; Pothuraju R; Ju J; Junker WM; Batra SK; Mallapragada S; Rachagani S
    J Control Release; 2019 Jan; 294():237-246. PubMed ID: 30576747
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enhancing sorafenib-mediated sensitization to gemcitabine in experimental pancreatic cancer through EMAP II.
    Awasthi N; Zhang C; Hinz S; Schwarz MA; Schwarz RE
    J Exp Clin Cancer Res; 2013 Mar; 32(1):12. PubMed ID: 23497499
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.